Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Nurix Therapeutics's Total Stockholders Equity for the quarter that ended in Feb. 2024 was $168.75 Mil. Nurix Therapeutics's Total Assets for the quarter that ended in Feb. 2024 was $312.67 Mil.
Therefore, Nurix Therapeutics's Equity to Asset Ratio for the quarter that ended in Feb. 2024 was 0.54.
The historical rank and industry rank for Nurix Therapeutics's Equity-to-Asset or its related term are showing as below:
NRIX'
s Equity-to-Asset Range Over the Past 10 Years
Min: -1.31 Med: 0.72 Max: 0.77
Current: 0.54
During the past 6 years, the highest Equity to Asset Ratio of Nurix Therapeutics was 0.77. The lowest was -1.31. And the median was 0.72.
NRIX's Equity-to-Asset is ranked worse than 60.52% of 1563
companies
in the Biotechnology industry
Industry Median: 0.66
vs NRIX: 0.54
Nurix Therapeutics Equity-to-Asset Historical Data
The historical data trend for Nurix Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Nurix Therapeutics's Equity-to-Asset
For the Biotechnology subindustry, Nurix Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nurix Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nurix Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Nurix Therapeutics's Equity-to-Asset falls into.
Nurix Therapeutics Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Nurix Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Nov. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Nurix Therapeutics Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Nurix Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Nurix Therapeutics (Nurix Therapeutics) Business Description
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NRIX has been successfully added to your 